Report overview
Bladder cancer is a disease in which malignant (cancer) cells form in the tissues of the bladder. Targeted therapy is a treatment that targets the cancer?s specific genes, proteins, or the tissue environment that contributes to cancer growth and survival. This type of treatment blocks the growth and spread of cancer cells and tries to limit damage to healthy cells.
This report contains market size and forecasts of Bladder Cancer Targeted Drug in Global, including the following market information:
Global Bladder Cancer Targeted Drug Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global top five companies in 2022 (%)
The global Bladder Cancer Targeted Drug market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Atezolizumab (Tecentriq) Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Bladder Cancer Targeted Drug include Pfizer, Merck KGaA, Roche, Astellas, Janssen Biotech, Bristol-Myers Squibb, Merck & Co. and Gilead Sciences, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bladder Cancer Targeted Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bladder Cancer Targeted Drug Market, by Type, 2018-2023, 2023-2030 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Type, 2022 (%)
Atezolizumab (Tecentriq)
Avelumab (Bavencio)
Erdafitinib (Balversa)
Other
Global Bladder Cancer Targeted Drug Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Other
Global Bladder Cancer Targeted Drug Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Bladder Cancer Targeted Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bladder Cancer Targeted Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Bladder Cancer Targeted Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Merck KGaA
Roche
Astellas
Janssen Biotech
Bristol-Myers Squibb
Merck & Co.
Gilead Sciences
